Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

News Conference News ACC 2025

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

March 31, 2025

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

April 08, 2024

AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup

News Conference News ACC 2023

AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup

March 09, 2023

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

News Conference News ACC 2023

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

Michael O'Riordan

March 09, 2023

On-site Machine Learning-Based FFRCT Feasible, Informative: TARGET

News Conference News ACC 2023

On-site Machine Learning-Based FFRCT Feasible, Informative: TARGET

March 04, 2023

What’s Going to Be Hot at ACC/WCC 2023?

News Opinion Editor's Corner ACC 2023

What’s Going to Be Hot at ACC/WCC 2023?

February 27, 2023

FLAVOUR FFR as Good as IVUS for Intermediate Coronary Stenoses

News Conference News ACC 2022

FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses

Michael O'Riordan

April 06, 2022

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

April 02, 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

News Conference News ACC 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

March 30, 2020

Colchicine Cost-effective in Canada, and Even in the US: COLCOT

News Conference News ACC 2020

Colchicine Cost-effective in Canada, and Even in the US: COLCOT

March 28, 2020

High Rate of Residual Ischemia After PCI Despite Excellent Angiographic Outcomes: DEFINE-PCI

News Conference News ACC 2019

High Rate of Residual Ischemia After PCI Despite Excellent Angiographic Outcomes: DEFINE-PCI

Michael O'Riordan

March 21, 2019

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

News Conference News ACC 2018

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

Yael L. Maxwell

March 12, 2018

CMR Perfusion Imaging Holds Its Own Against Invasive Approach to Managing Stable Angina

News Conference News ACC 2017

CMR Perfusion Imaging Holds Its Own Against Invasive Approach to Managing Stable Angina

March 22, 2017

DECISION-CTO: Optimal Medical Therapy With or Without Stenting For Coronary Chronic Total Occlusion

Presentation ACC 2017

DECISION-CTO: Optimal Medical Therapy With or Without Stenting For Coronary Chronic Total Occlusion

Presenter: Seung-Jung Park

March 20, 2017

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

News Conference News ACC 2017

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

Yael L. Maxwell

March 19, 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Conference News ACC 2016

Hints of What’s to Come in New Coronary Revascularization AUC

April 12, 2016

News Conference News ACC 2016

‘Enhanced’ Multicellular Stem Cell Therapy Improves Clinical Outcomes in Heart Failure: ixCELL-DCM Study

Michael O'Riordan

April 04, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.